40.65
Tonix Pharmaceuticals Holding Corp stock is traded at $40.65, with a volume of 703.57K.
It is up +5.83% in the last 24 hours and up +115.31% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$38.41
Open:
$38.11
24h Volume:
703.57K
Relative Volume:
0.48
Market Cap:
$291.38M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-3.6101
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
+2.19%
1M Performance:
+115.31%
6M Performance:
+121.53%
1Y Performance:
-88.32%
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TNXP
Tonix Pharmaceuticals Holding Corp
|
40.65 | 291.38M | 0 | -121.02M | -114.09M | -11.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
Feb-17-16 | Reiterated | Oppenheimer | Outperform |
Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
Jun-12-15 | Initiated | Oppenheimer | Outperform |
Feb-17-15 | Reiterated | ROTH Capital | Buy |
Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Announces Poster Presentation at the Annua - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces Poster Presentation at the - GlobeNewswire
Northern Trust Corp Acquires New Shares in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) - Defense World
Tonix Pharmaceuticals (TNXP) Price Target Raised to $65 by Alliance Global Partners | TNXP Stock News - GuruFocus
Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - Defense World
Tonix Pharmaceuticals: August PDUFA Date For Fibromyalgia Med A Risky Bet (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights - mx.advfn.com
How the (TNXP) price action is used to our Advantage - news.stocktradersdaily.com
Tonix Pharmaceuticals (TNXP) Stock Surges Over 10%: What's Fueling the Rally and What's Next? - Daily Chhattisgarh News
What's Going On With Tonix Pharmaceuticals Stock? - Benzinga
TNXP: Preparations Continue for Potential Commercial Launch of TNX-102 SL in Fibromyalgia… - Yahoo Finance
Tonix Pharmaceuticals CEO Highlights Strategic Vision at Healthcare Showcase - citybuzz -
Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase - GlobeNewswire
Tonix begins trial for stress reaction treatment By Investing.com - Investing.com South Africa
Tonix begins trial for stress reaction treatment - Investing.com Australia
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 O - GuruFocus
Tonix Pharmaceuticals (TNXP) Commences Phase 2 Trial for Stress Disorder Treatment | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction - marketscreener.com
Tonix Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
DoD Backs Revolutionary Acute Stress Treatment: First Patient Dosed in $3M Phase 2 Trial - Stock Titan
Tonix Pharmaceuticals (TNXP) Stock Surges Following Insider Buying And Q1 Results - Benzinga
Stocks To Watch: Tonix Pharmaceuticals Sees RS Rating Jump To 89 - inkl
Tonix Pharmaceuticals Recruits Seasoned Industry Atty As GC - Law360
Tonix Pharma Stock Soars After Roping In Former Celgene Corp Executive Joseph Hand: Retail Gets More Positive - Investing.com India
Tonix Pharmaceuticals Names Joseph Hand as General Counsel and Executive Vice President of Operations - citybuzz -
Tonix Pharmaceuticals Appoints Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations - citybiz
Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EV - GuruFocus
Tonix Pharmaceuticals (TNXP) Appoints New General Counsel and EVP of Operations | TNXP Stock News - GuruFocus
Tonix Pharma Appoints New General Counsel and EVP - TipRanks
Tonix Pharmaceuticals Announces Appointment of Joseph Hand, - GlobeNewswire
Former Celgene $74B Deal Leader Joins Tonix as EVP Before Critical Fibromyalgia Drug Decision - Stock Titan
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Resul - GuruFocus
Tonix Pharmaceuticals Q1 2025 Earnings: EPS Loss of $2.84 Beats - GuruFocus
Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Tonix Pharma earnings beat by $22.84, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals reports annual meeting results By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals reports annual meeting results - Investing.com Australia
Tonix showcases promising gastric cancer data at AACR Conference - Proactive financial news
(TNXP) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Tonix Pharma drops after Q4 revenue miss - MSN
Tonix Pharmaceuticals: Looking Past FDA Approval To Challenging Commercial Opportunity - Seeking Alpha
Tonix Pharmaceuticals Reveals Promising Preclinical Data for Cancer Immunotherapy TNX-1700 - citybuzz -
Tonix Pharma Unveils Promising Cancer Treatment Data - TipRanks
Tonix Pharmaceuticals Presented Preclinical Data on Gastric - GlobeNewswire
Tonix Pharmaceuticals (TNXP) Showcases Promising Cancer Research at AACR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Canc - GuruFocus
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):